Related references
Note: Only part of the references are listed.Parkinson's disease-related network topographies characterized with resting state functional MRI
An Vo et al.
HUMAN BRAIN MAPPING (2017)
Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study
Keisuke Suzuki et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease
Takeya Kitta et al.
INTERNATIONAL JOURNAL OF UROLOGY (2016)
The difference of apparent diffusion coefficient in the middle cerebellar peduncle among parkinsonian syndromes: Evidence from a meta-analysis
Wataru Sako et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2016)
Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases
Paul J. Mattis et al.
NEUROLOGY (2016)
A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
Tomoyoshi Kondo et al.
CLINICAL NEUROPHARMACOLOGY (2015)
Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson's Disease: A Meta-analysis of Randomized Controlled Trials
Yingqun Tao et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials
M. Chondrogiorgi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation
Wataru Sako et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Reduced Alpha-Synuclein in Cerebrospinal Fluid in Synucleinopathies: Evidence From a Meta-analysis
Wataru Sako et al.
MOVEMENT DISORDERS (2014)
Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs
Thomas J. Moore et al.
JAMA INTERNAL MEDICINE (2014)
Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis
Wanqiang Chen et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2013)
Caffeine consumption and risk of dyskinesia in CALM-PD
Anne-Marie A. Wills et al.
MOVEMENT DISORDERS (2013)
Adenosine A2A receptor gene disruption protects in an a-synuclein model of Parkinson's disease
Anil Kachroo et al.
ANNALS OF NEUROLOGY (2012)
Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
Emmanuelle Pourcher et al.
PARKINSONISM & RELATED DISORDERS (2012)
Modulation of Striatal Projection Systems by Dopamine
Charles R. Gerfen et al.
ANNUAL REVIEW OF NEUROSCIENCE, VOL 34 (2011)
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
A. F. Ramlackhansingh et al.
NEUROLOGY (2011)
Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease The STRIDE-PD Study
Fabrizio Stocchi et al.
ANNALS OF NEUROLOGY (2010)
Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2010)
Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry
Alexxai V. Kravitz et al.
NATURE (2010)
Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
H. H. Fernandez et al.
PARKINSONISM & RELATED DISORDERS (2010)
Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
ARCHIVES OF NEUROLOGY (2009)
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces Off' time in Parkinson's disease:: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter A. LeWitt et al.
ANNALS OF NEUROLOGY (2008)
Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctuations
Robert A. Hauser et al.
MOVEMENT DISORDERS (2008)
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
M. Stacy et al.
NEUROLOGY (2008)
Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease
Anti Kalda et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2006)
A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
MA Hernán et al.
ANNALS OF NEUROLOGY (2002)
Neuroprotection by adenosine A(2A) receptor blockade in experimental models of Parkinson's disease
K Ikeda et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Share Paper
